These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 23939307)

  • 1. Interaction between α-synuclein and tau genotypes and the progression of Parkinson's disease.
    Huang Y; Rowe DB; Halliday GM
    J Parkinsons Dis; 2011; 1(3):271-6. PubMed ID: 23939307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interaction of alpha-synuclein and tau genotypes in Parkinson's disease.
    Mamah CE; Lesnick TG; Lincoln SJ; Strain KJ; de Andrade M; Bower JH; Ahlskog JE; Rocca WA; Farrer MJ; Maraganore DM
    Ann Neurol; 2005 Mar; 57(3):439-43. PubMed ID: 15732111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variants in the SNCA gene associate with motor progression while variants in the MAPT gene associate with the severity of Parkinson's disease.
    Wang G; Huang Y; Chen W; Chen S; Wang Y; Xiao Q; Liu J; Fung VS; Halliday G; Chen S
    Parkinsonism Relat Disord; 2016 Mar; 24():89-94. PubMed ID: 26776090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SNCA Gene, but Not MAPT, Influences Onset Age of Parkinson's Disease in Chinese and Australians.
    Huang Y; Wang G; Rowe D; Wang Y; Kwok JB; Xiao Q; Mastaglia F; Liu J; Chen SD; Halliday G
    Biomed Res Int; 2015; 2015():135674. PubMed ID: 25960998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of alpha-synuclein Rep1 polymorphism and Parkinson's disease: influence of Rep1 on age at onset.
    Hadjigeorgiou GM; Xiromerisiou G; Gourbali V; Aggelakis K; Scarmeas N; Papadimitriou A; Singleton A
    Mov Disord; 2006 Apr; 21(4):534-9. PubMed ID: 16250025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of interaction of SNCA and MAPT genotypes in Parkinson's disease.
    Botta-Orfila T; Ezquerra M; Ríos J; Fernández-Santiago R; Cervantes S; Samaranch L; Pastor P; Martí MJ; Muñoz E; Valldeoriola F; Aguilar M; Calopa M; Hernández-Vara J; Tolosa E
    Eur J Neurol; 2011 Mar; 18(3):e32. PubMed ID: 21054681
    [No Abstract]   [Full Text] [Related]  

  • 7. Australian data and meta-analysis lend support for alpha-synuclein (NACP-Rep1) as a risk factor for Parkinson's disease.
    Mellick GD; Maraganore DM; Silburn PA
    Neurosci Lett; 2005 Feb; 375(2):112-6. PubMed ID: 15670652
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAPT H1 haplotype is associated with enhanced α-synuclein deposition in dementia with Lewy bodies.
    Colom-Cadena M; Gelpi E; Martí MJ; Charif S; Dols-Icardo O; Blesa R; Clarimón J; Lleó A
    Neurobiol Aging; 2013 Mar; 34(3):936-42. PubMed ID: 22819391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alpha-synuclein repeat variants and survival in Parkinson's disease.
    Chung SJ; Biernacka JM; Armasu SM; Anderson K; Frigerio R; Aasly JO; Annesi G; Bentivoglio AR; Brighina L; Chartier-Harlin MC; Goldwurm S; Hadjigeorgiou G; Jasinska-Myga B; Jeon BS; Kim YJ; Krüger R; Lesage S; Markopoulou K; Mellick G; Morrison KE; Puschmann A; Tan EK; Crosiers D; Theuns J; Van Broeckhoven C; Wirdefeldt K; Wszolek ZK; Elbaz A; Maraganore DM;
    Mov Disord; 2014 Jul; 29(8):1053-7. PubMed ID: 24578302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants.
    Heckman MG; Elbaz A; Soto-Ortolaza AI; Serie DJ; Aasly JO; Annesi G; Auburger G; Bacon JA; Boczarska-Jedynak M; Bozi M; Brighina L; Chartier-Harlin MC; Dardiotis E; Destée A; Ferrarese C; Ferraris A; Fiske B; Gispert S; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lin CH; Lohmann K; Loriot MA; Lynch T; Mellick GD; Mutez E; Opala G; Park SS; Petrucci S; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Tomiyama H; Uitti RJ; Valente EM; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Xiromerisiou G; Maraganore DM; Farrer MJ; Ross OA;
    Neurobiol Aging; 2014 Jan; 35(1):266.e5-14. PubMed ID: 23962496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-synuclein polymorphisms are associated with Parkinson's disease in a Saskatchewan population.
    Rajput A; Vilariño-Güell C; Rajput ML; Ross OA; Soto-Ortolaza AI; Lincoln SJ; Cobb SA; Heckman MG; Farrer MJ; Rajput A
    Mov Disord; 2009 Dec; 24(16):2411-4. PubMed ID: 19890971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cerebrospinal fluid Tau/α-synuclein ratio in Parkinson's disease and degenerative dementias.
    Parnetti L; Chiasserini D; Bellomo G; Giannandrea D; De Carlo C; Qureshi MM; Ardah MT; Varghese S; Bonanni L; Borroni B; Tambasco N; Eusebi P; Rossi A; Onofrj M; Padovani A; Calabresi P; El-Agnaf O
    Mov Disord; 2011 Jul; 26(8):1428-35. PubMed ID: 21469206
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collaborative analysis of alpha-synuclein gene promoter variability and Parkinson disease.
    Maraganore DM; de Andrade M; Elbaz A; Farrer MJ; Ioannidis JP; Krüger R; Rocca WA; Schneider NK; Lesnick TG; Lincoln SJ; Hulihan MM; Aasly JO; Ashizawa T; Chartier-Harlin MC; Checkoway H; Ferrarese C; Hadjigeorgiou G; Hattori N; Kawakami H; Lambert JC; Lynch T; Mellick GD; Papapetropoulos S; Parsian A; Quattrone A; Riess O; Tan EK; Van Broeckhoven C;
    JAMA; 2006 Aug; 296(6):661-70. PubMed ID: 16896109
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of ethnicity on the association of MAPT H1 haplotypes and subhaplotypes in Parkinson's disease.
    Winkler S; König IR; Lohmann-Hedrich K; Vieregge P; Kostic V; Klein C
    Eur J Hum Genet; 2007 Nov; 15(11):1163-8. PubMed ID: 17637803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic variability in the SNCA gene influences alpha-synuclein levels in the blood and brain.
    Fuchs J; Tichopad A; Golub Y; Munz M; Schweitzer KJ; Wolf B; Berg D; Mueller JC; Gasser T
    FASEB J; 2008 May; 22(5):1327-34. PubMed ID: 18162487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypomethylation of SNCA in blood of patients with sporadic Parkinson's disease.
    Ai SX; Xu Q; Hu YC; Song CY; Guo JF; Shen L; Wang CR; Yu RL; Yan XX; Tang BS
    J Neurol Sci; 2014 Feb; 337(1-2):123-8. PubMed ID: 24326201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Exploring gene-environment interactions in Parkinson's disease.
    McCulloch CC; Kay DM; Factor SA; Samii A; Nutt JG; Higgins DS; Griffith A; Roberts JW; Leis BC; Montimurro JS; Zabetian CP; Payami H
    Hum Genet; 2008 Apr; 123(3):257-65. PubMed ID: 18210157
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TAU haplotype and the Saitohin Q7R gene polymorphism do not influence CSF Tau in Alzheimer's disease and are not associated with frontotemporal dementia or Parkinson's disease.
    Johansson A; Zetterberg H; Håkansson A; Nissbrandt H; Blennow K
    Neurodegener Dis; 2005; 2(1):28-35. PubMed ID: 16909000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tau protein: relevance to Parkinson's disease.
    Lei P; Ayton S; Finkelstein DI; Adlard PA; Masters CL; Bush AI
    Int J Biochem Cell Biol; 2010 Nov; 42(11):1775-8. PubMed ID: 20678581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tau haplotypes regulate transcription and are associated with Parkinson's disease.
    Kwok JB; Teber ET; Loy C; Hallupp M; Nicholson G; Mellick GD; Buchanan DD; Silburn PA; Schofield PR
    Ann Neurol; 2004 Mar; 55(3):329-34. PubMed ID: 14991810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.